# デ・ウエスタン・セラピテクス研究所（4576） FY2022 Q2 四半期報告書

Source: Komori (komori.app) — https://komori.app/company/4576/filing/2022-q2
提出日: 2022-08-09
対象期間: 2022-04-01 〜 2022-06-30
企業ページ: https://komori.app/company/4576
原本（EDINET）: https://disclosure2dl.edinet-fsa.go.jp/searchdocument/pdf/S100OU2V.pdf

## 事業

De Westen Therapeutics Laboratory is engaged in drug discovery as its primary business, operating in a single segment (pharmaceuticals). In the second quarter of the consolidated cumulative period, two products were launched: Granatech Eye Drops 0.4% (glaucoma treatment) and DW-1002 (ophthalmic surgical adjunct). Sales were 210,000,000 JPY for the quarter, with cost of sales 13,000,000 JPY. SG&A was 329,000,000 JPY, consisting of R&D of 199,000,000 JPY and other SG&A of 129,000,000 JPY. Operating loss was 132,000,000 JPY. Non-operating income included foreign exchange gains of 32,000,000 JPY and non-operating expenses of 13,000,000 JPY, resulting in ordinary loss of 118,000,000 JPY and quarterly net loss attributable to parent company shareholders of 110,000,000 JPY. Quarterly comprehensive income was negative 119,372,000 JPY. Total assets were 2,287,000,000 JPY, current assets 2,003,000,000 JPY, cash and deposits 1,749,000,000 JPY. Fixed assets 283,000,000 JPY. Liabilities total 358,000,000 JPY, current liabilities 174,000,000 JPY, fixed liabilities 184,000,000 JPY. Net assets 1,928,000,000 JPY with 83.5% equity ratio. Cash and cash equivalents at end of period 1,749,315,000 JPY. Operating cash flow (CFO) -130,420,000 JPY, investing cash flow (CFI) -4,077,000 JPY, financing cash flow (CFF) -76,391,000 JPY. Ending cash and cash equivalents 1,749,315,000 JPY. R&D expenses total 199,000,000 JPY. Revenue from DW-1001 development, DW-1002/Granatech royalties and DW-1001 milestone income contributed to sales.

## 数字

- 研究開発費: 2億円
- 設備投資: 4百万円
- フリーキャッシュフロー: -1億円

## 地域別

- 日本 / 売上高 1億円
- オランダ / 売上高 98百万円

## 有価証券報告書にだけ載る項目

- 大株主: 保有比率と、その変動。
- 役員: 取締役の氏名、在任年数、独立性。
- 設備の状況: 拠点、帳簿価額、敷地面積。
- 沿革: 沿革と中期目標。